In a multi-year analysis of cervical precancers, data indicate that the incidence of cancers caused by human papillomavirus (HPV) types 16 and 18, which have been targeted by vaccination, has declined.
According to a new study, only about 16% of U.S. adolescents have received the complete vaccination against human papillomavirus (HPV) by the time they turn 13 years of age, despite national recommendations for vaccination at ages 11-12.
In an analysis of insurance claims for 1.8 million U.S. children with 2,950 recorded seizures, researchers found that the risk of hospitalization for seizures was 24% lower in rotavirus-vaccinated children.
The Food and Drug Administration has approved the use of the nine-valent human papillomavirus (HPV) vaccine in women and men ages 27-45. The Advisory Committee on Immunization Practices (ACIP) is scheduled to review further information at its February 2019 meeting, with a potential vote at that time. Insurance reimbursement often is based on ACIP guidance.
About 14 million additional preteens, beyond those who will receive the HPV shot based on current rates, will need to be immunized between now and 2026 to reach the 80% vaccination rate goal, an American Cancer Society report indicates.
Just-released data indicate human papillomavirus (HPV) vaccination completion in U.S. adolescents increased by five percentage points from 2016 to 2017, and initiation of the vaccine has gone up 5.1 percentage points, on average, each year since 2013.
It is expensive to respond to and control measles outbreaks in the United States. Primary outbreak prevention should focus on vaccination of travelers and encouragement of routine vaccine acceptance by those who currently are hesitant to have their children vaccinated.